Expert Perspectives
Perlmutter Cancer Center director and co-creator of the HapImmune platform discusses the technology’s potential.
Advancing Science
In a phase 2 trial, pairing an mRNA vaccine with pembrolizumab improved relapse-free survival in advanced melanoma.
Practice-Changing Medicine
Patient’s decision to forego radical cystectomy exemplifies opportunity to expand TMT as a treatment option.
Expanding their suite of AI tools for breast imaging, researchers develop a machine learning model for DCE-MRI.
Research test developed at Perlmutter Cancer Center pinpoints changes in a newly identified autoantibody panel.
Perlmutter Cancer Center joins national collaborative to address unmet needs through innovative early-phase trials.
Vote Now